Compare SLI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | GHRS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2011 | 2021 |
| Metric | SLI | GHRS |
|---|---|---|
| Price | $3.66 | $21.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.25 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.7M | 260.1K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.49 | $10.67 |
| 52 Week High | $6.40 | $24.66 |
| Indicator | SLI | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 61.12 |
| Support Level | $3.04 | $12.41 |
| Resistance Level | $3.69 | $22.88 |
| Average True Range (ATR) | 0.24 | 1.42 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 12.20 | 61.56 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company the company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.